(Q37718340)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

New antiarrhythmic drugs for treatment of atrial fibrillation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1

Dobromir Dobrev

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

22 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

375

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1212-1223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

9721

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Epidemiological profile of atrial fibrillation: a contemporary perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Innovative approaches to anti-arrhythmic drug therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Controversies in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Ablation of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

New ideas about atrial fibrillation 50 years on.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial remodeling and atrial fibrillation: mechanisms and implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Defective cardiac ryanodine receptor regulation during atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Stationary and drifting spiral waves of excitation in isolated cardiac muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Electrical remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial L-type Ca2+ currents and human atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

L-type Ca2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action poten

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK,ACh channels in patients with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Recurrence of atrial fibrillation after internal cardioversion of persistent atrial fibrillation: prognostic importance of electrophysiologic parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Electrical, contractile and structural remodeling during atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

The role of stretch-activated channels in atrial fibrillation and the impact of intracellular acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Rhythm control versus rate control for atrial fibrillation and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Therapeutic considerations in applying rate control therapy for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Effect of dronedarone on cardiovascular events in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Amiodarone as paradigm for developing new drugs for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Local venous response to N-desethylamiodarone in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

The novel antiarrhythmic drug dronedarone: comparison with amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Increased mortality after dronedarone therapy for severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Involvement of nitric oxide in amiodarone- and dronedarone-induced coronary vasodilation in guinea pig heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Effect of hypertension on anticoagulated patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Amiodarone pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

The mechanism of atrial antiarrhythmic action of RSD1235.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial-selective sodium channel blockers: do they exist?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Clinical pharmacokinetics of ranolazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

"Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Inward rectifier potassium currents as a target for atrial fibrillation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: potential role for early remodeling in atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial structural remodeling as an antiarrhythmic target

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Inhibition of the renin-angiotensin system: effects on tachycardia-induced early electrical remodelling in rabbit atrium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Valsartan for prevention of recurrent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Aldosterone production is activated in failing ventricle in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Raised plasma aldosterone and natriuretic peptides in atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Statins and polyunsaturated fatty acids for treatment of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Biological therapies for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960096-7

7 January 2021

10.1016/S0140-6736(10)60096-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20334907%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference